WEBULL
WebtradeDownload

Nektar Therapeutics (NKTR) Draws Fresh Eczema Buzz Following A 72% Undervalued Narrative

Simply Wall St · 2d ago

Nektar Therapeutics (NKTR) has drawn fresh attention after its eczema and hair loss drug candidate, positioned as an alternative for patients who do not respond to Dupixent, emerged as a key focus for analysts.

Despite new interest in its eczema and hair loss program, Nektar Therapeutics’ share price has been volatile. The 1-day share price return is 3.07%, but the 90-day share price return has fallen 51.28%, while the 3-year total shareholder return is 446.05%. This pattern suggests that earlier enthusiasm is now being reassessed in light of execution risks and valuation concerns.

Spot emerging biopharma stories beyond Nektar Therapeutics by scanning a curated 19 high quality undiscovered gems featuring companies with strong fundamentals that the wider market may not be watching closely yet.

After a three year surge and a sharp 90 day pullback, Nektar Therapeutics now splits opinion. Is the meaningful upside still ahead, or did most of it already play out in the rear-view mirror, as the valuation section shows next?

Most Popular Narrative: 72% Undervalued

Nektar Therapeutics closed at $37.26 while the most followed narrative anchors fair value at about $133.08. The entire debate hinges on whether rezpegaldesleukin and the broader pipeline can turn a development stage biotech with losses into a cash generative immunology platform by the late 2020s.

The reported pool of more than 15 million moderate to severe atopic dermatitis patients and roughly 6.7 million alopecia areata patients in the United States with relatively low current use of systemic therapies highlights substantial untreated demand that rezpegaldesleukin could address, with potential to scale Nektar Therapeutics’ top line and improve operating leverage if adoption materializes.

See why 13 investors see Nektar Therapeutics as 72% undervalued.

Result: Fair Value of $133.08 (UNDERVALUED)

Still, the narrative around Nektar Therapeutics could crack if late stage rezpegaldesleukin trials stumble, or if ongoing losses eventually force dilutive funding at weak prices.

Find out about the key risks to this Nektar Therapeutics narrative.

Another View: What Nektar Therapeutics Looks Like On Sales

The analyst narrative points to Nektar Therapeutics trading 72% below a $133.08 fair value anchor. On a simpler yardstick, the current P/S ratio of 23.3x looks heavy next to both the US Biotechs industry at 10.1x and a fair ratio of 9.2x, which implies meaningful valuation risk if expectations cool further. Which lens do you trust more when the stock is already pricing in rich sales multiples?

For readers who lean on comparative ratios rather than long range narratives, the gap between today’s P/S, peers and that lower fair ratio can be a useful reality check on how much optimism is already baked in, and whether rezpegaldesleukin has to clear a very high bar for the share price to keep up with the current tag, See what the numbers say about this price — find out in our valuation breakdown.

NasdaqCM:NKTR P/S Ratio as at Nov 2026
NasdaqCM:NKTR P/S Ratio as at Nov 2026

Next Steps

Unsure whether the current mix of excitement and doubt around Nektar Therapeutics feels justified to you? Act quickly, review the data for yourself, and weigh both sides by starting with the 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond Nektar Therapeutics?

If Nektar Therapeutics has you thinking harder about risk, reward, and timing, do not stop here. Use the screener to surface fresh opportunities that fit your style.